Medical Instruments & Supplies

(CFN) CareFusion Buying Rowa for $150 Million

Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million.

Rowa, which has customers in 30 countries, specializes in high-speed...

12Jul2011 | | 0 comments | Continued

(CFN) CareFusion Decides to Acquire Medegen for $225 Million

CareFusion Corporation (CFN) has decided to acquire Medegen for $225 million in cash. CareFusion expects the acquisition to be neutral to the adjusted earnings per share in the first year of operations and increasingly accretive thereafter....

7Apr2010 | | 0 comments | Continued

(CFN) CareFusion Corporation Beats Consensus Estimates

CareFusion Corporation (CFN) recently reported second quarter fiscal 2010 earnings per share of 39 cents, marginally beating the Zacks Consensus Estimate of 38 cents, but lower than the year-ago earnings of 50 cents.

Total revenues...

10Feb2010 | | 0 comments | Continued

(CFN) CareFusion Corporation Enters Agreement with Masimo

CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry...

14Nov2009 | | 0 comments | Continued

(BAX) Baxter International Discussed Long-Term Goals

Baxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and development (R&D) programs at its recently concluded Investor Conference in Chicago.

The long-term (5-year) financial objectives are as follows:

(HAE) Haemonetics Corporation Inks Software Deal

Haemonetics Corp. (HAE) yesterday announced that it has entered into a deal with Blood Centers of America Inc. (“BCA”), a cooperative of community blood centers, which will provide BCA members access to Haemonetics’ blood management software.

Specifically, the agreement...

18Sep2009 | | 0 comments | Continued

(ACL) Alcon Aquires Swiss Company and Expands Pipeline

Earlier this week, Alcon Inc. (ACL) signed a definitive agreement for the acquisition of Swiss biotech company ESBATech AG. Alcon will pay $150 million in cash at closing. Besides this, Alcon may pay up to $439 million on the achievement of future research and development milestones.

With...

18Sep2009 | | 0 comments | Continued

(BAX) Top Health Equity Funds – Mutual Fund Commentary

Today we are featuring top-performing “Health” equity mutual funds, which primarily invest in equity securities of healthcare and related companies.

Investors can find such funds by checking out the entire list of the | 0 comments | Continued

(BAX) Baxter International Fails to Deliver Swine Flu Vaccine

Baxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government to supply required quantities of swine flu vaccine, Celvapan. The company has supplied only half of the 400,000 doses of Celvapan it had agreed to supply by the end of Aug 2009.

Britain’s...

16Sep2009 | | 0 comments | Continued

(HAE) Haemonetics Corporation Acquires Engineering and Research Associates Inc

Haemonetics Corporation (HAE) has recently acquired the blood collection and processing business of Engineering and Research Associates Inc., commonly known as SEBRA. The transaction is worth $12.5 million in cash and is expected to be completed in...

9Sep2009 | | 0 comments | Continued

(NURO) NeuroMetrix Inc Raises Funds

NeuroMetrix Inc. (NURO) entered into a private placement transaction with institutional investors for $18.68 million worth of its common stock. Per the agreement, the company will sell 8,816,521 shares and warrants to purchase up to 8,375,695 additional shares of common...

9Sep2009 | | 0 comments | Continued

(BSX) Positive SYNTAX for Boston Scientific Stent

Boston Scientific Corporation (BSX) recently came out with its two-year SYNTAX clinical data that do not typify any statistically significant difference between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery. The PCI was performed using the...

8Sep2009 | | 0 comments | Continued

(BCR) C.R. Bard – Bull of the Day

C.R. Bard (BCR) operates in vascular, urology, oncology and surgical specialty markets. These end-markets should remain insulated from the current economic turmoil.

Many of the company’s products are used in interventional medicine — life-saving surgical procedures. Future quarters...

4Sep2009 | | 0 comments | Continued

(COO) Cooper Companies Misses Estimates by 13%

The Cooper Companies Inc. (COO) reported fiscal third-quarter results yesterday after market close. The company posted GAAP earnings of $21.9 million or 48 cents per share, compared to $17.9 million or 39 cents per share in the year-ago period. Excluding restructuring charges, pro...

4Sep2009 | | 0 comments | Continued

(BDX) Becton, Dickinson and Company Receives $52 Million Government Order

Becton, Dickinson and Company (BDX) received an order from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) for the purchase of syringes and needles, sharps collectors and alcohol swabs for use in national...

4Sep2009 | | 0 comments | Continued

(BSX) Boston Scientific Registers Positive Results From MADIT Trial

BSX: Positive Results from MADIT Trial

Boston Scientific Corporation
(BSX) announced positive final results from its landmark MADIT-CRT trial. The MADIT trial was conducted to evaluate the effectiveness of the company’s cardiac resynchronization therapy defibrillators...

2Sep2009 | | 0 comments | Continued

(BSX) Boston Scientific is Ready For MADIT Results

Boston Scientific Corp. (BSX) is geared up for its landmark MADIT-CRT trial final results, which will be announced on Sept 1. The MADIT trial is evaluating the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable...

31Aug2009 | | 0 comments | Continued

(KNSY) Kensey Beats Consensus Estimate

Kensey Nash Corp. (KNSY) recently reported strong results for the fourth quarter and full year 2009. Quarterly profit came in at 41 cents per share, compared to the Zacks Consensus Estimate of 38 cents and the year-ago loss of 9 cents per share.

Quarterly...

24Aug2009 | | 0 comments | Continued

($BAX) Baxter International – ROE of 35%, soaring past the industry average of 8%$

Baxter International Inc. (BAX) recently posted second-quarter earnings of 96 cents per share, topping the consensus estimate by 2% and surpassing the previous year’s 85 cents. The company also upped its full-year earnings guidance, and analysts followed suit.

Company...

23Jul2009 | | 0 comments | Continued

(BAX) Medical Devices – Industry Outlook

Since the beginning of the global economic crisis, medical device stocks have fared slightly worse than the overall market, losing roughly 400 bps more than the S&P500 (-31%) since September 1, 2008, on a market weighted basis. We continue to recommend that investors focus on companies providing...

14Jul2009 | | 0 comments | Continued

(MMSI) Merit Medical Systems, Inc. – Aggressive Growth – Zacks Rank Buy

Merit Medical Systems, Inc. (MMSI) boosted its net income by 28% in its latest earnings report.

Company Description

Merit Medical Systems, Inc. produces single-use medical products of high quality and superior value primarily for use in...

8Jul2009 | | 0 comments | Continued

(BAX) Baxter International Inc. – Growth And Income – Zacks Rank Buy

Baxter International Inc. (BAX) is seeing upbeat estimates ahead of announcing second-quarter results in early July. Analysts are calling for full-year earnings of $3.77 per share, an upward revision of 2 cents over the past 3 months.

Company Description

Baxter...

23Jun2009 | | 0 comments | Continued

(COV) Covidien Limited – Value – Zacks Rank Buy

Covidien Limited (COV), the medical device manufacturer, has surprised on estimates 7 quarters in a row. Will it do it again on Apr 30? Second quarter estimates have risen by nearly 17% in the last 3 months. COV has a forward P/E of 11.35.

Company Description

Covidien...

23Apr2009 | | 0 comments | Continued

(BDX) Becton, Dickinson and Company – Growth And Income – Zacks Rank Buy

Becton, Dickinson and Company (BDX) keeps seeing bullish forecasts on strong fundamentals as the company prepares to report early next week. Analysts are projecting earnings growth of 10.5% for the fiscal year ending September 2009 followed by growth of 10.5% more in fiscal 2010.

Company...

23Apr2009 | | 0 comments | Continued

(COO) The Cooper Companies, Inc – Value – Zacks Rank Buy

Cooper Companies, Inc. (COO) analysts are raising estimates and shares are rising consistently.

Company Description

The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and markets healthcare...

20Apr2009 | | 0 comments | Continued

(BDX) Becton Dickinson and Company – Growth And Income – Zacks Rank Buy

Becton, Dickinson and Company (BDX) continues to see bullish forecasts from Wall Street. Analysts are projecting earnings growth of 10% for the fiscal year ending September 2009 followed by growth of 10% more in fiscal 2010.

Company Description

Becton,...

2Apr2009 | | 0 comments | Continued

(COO) The Cooper Companies, Inc. – Momentum – Zacks Rank Buy

The Cooper Companies, Inc. (COO) continues to perform well in a touch market, with the company’s recent first-quarter results coming in ahead of expectations.

Company Description

The Cooper Companies, Inc., through its...

2Apr2009 | | 0 comments | Continued

(COO) Cooper Companies, Inc – Aggressive Growth – Zacks Rank Buy

Cooper Companies, Inc. (COO) just reported solid revenue and earnings growth. Margins are improving and shares are on the rise.

Company Description

The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and...

12Mar2009 | | 0 comments | Continued

(KNSY) Kensey Nash Corp. – Aggressive Growth – Zacks Rank Buy

Kensey Nash Corp. (KNSY) has once again reported record earnings and should post double-digit growth for the next 2 years.

Company Description

Kensey Nash Corporation designs, develops, manufactures, and processes proprietary biomaterials...

27Feb2009 | | 0 comments | Continued

(BAX) Baxter International, Inc. – Growth And Income – Zacks Rank Buy

Baxter International Inc. (BAX) recently declared a quarterly dividend of 26 cents per share, noting that it is payable on April 1 to shareholders of record as of the close of business on March 10.

Company Description

Baxter International develops, manufactures...

27Feb2009 | | 0 comments | Continued